By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > CVC seeks €700mn for its Italian pharma outsourcer Genetic
News

CVC seeks €700mn for its Italian pharma outsourcer Genetic

News Room
Last updated: 2024/11/09 at 12:32 PM
By News Room
Share
3 Min Read
SHARE

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Private equity group CVC Capital Partners is on the hunt for a buyer for its majority stake in Italian pharmaceutical outsourcer Genetic Group, in a deal that they hope will value the business at about €700mn, according to people familiar with the matter.

Luxembourg-based CVC, which has €193bn under management, has hired advisers from Rothschild to help it sell its 60 per cent stake in the Salerno-based contract manufacturer, the people said.

The company produces technology for asthma inhalers, nasal sprays and medical devices used to treat respiratory disease and eye problems.

Genetic’s founder Rocco Pavese and his family, who retained a minority stake in the business after CVC’s acquisition in 2020, would like to remain a shareholder following any possible transaction.

Advisers are pushing to complete a sale in the first half of next year, although it may not go ahead, the people said.

CVC has doubled earnings before interest, taxes, depreciation and amortisation at Genetic to about €50mn since taking over the business.

Private equity has invested heavily in the pharmaceutical supply chain in recent years as an avenue to benefit from the boom in drug development, without taking the risk of investing in experimental medicines.

CVC, Rothschild and Genetic declined to comment.

The contract manufacturing industry has grown significantly as big drugmakers have shed in-house manufacturing operations to save costs, with the sector projected to be worth more than $220bn by 2030, according to data from consultancy Alvaraz and Marsal.

Genetic, which was established in 2000, owns the intellectual property of about 50 products that it sells in more than 30 countries. It manufactures the products on behalf of pharmaceutical clients. The group is likely to draw interest from other private equity firms.

Private equity groups have bought several smaller specialised contract manufacturers this year, including FairJourney Biologics, Avid Bioservices and Single Use Support.

CVC owns the business through its strategic opportunities fund, which usually holds on to businesses for the long-term.

The private equity firm floated in Amsterdam in April. Its shares have risen close to 60 per cent to €22.25 compared with the offer price at the initial public offering, giving the group a market value of more than €23bn.

Read the full article here

News Room November 9, 2024 November 9, 2024
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Military briefing: How Iran is preparing for Israeli or US strikes

Iran has been seeking to bolster its air defences as the military…

President Trump holds Cabinet meeting

Watch full video on YouTube

How Tesla lost some of its biggest fans

Watch full video on YouTube

Is private equity becoming a money trap?

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Iran has increased enriched uranium by 50%, says UN watchdog

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

News

Military briefing: How Iran is preparing for Israeli or US strikes

By News Room
News

Is private equity becoming a money trap?

By News Room
News

Iran has increased enriched uranium by 50%, says UN watchdog

By News Room
News

Israel blocks Arab foreign ministers from meeting in West Bank

By News Room
News

South Africa faces backlash over plan to change law for Musk’s Starlink

By News Room
News

Opec+ to boost oil output for third consecutive month

By News Room
News

Turkey detains five mayors in latest crackdown on opposition

By News Room
News

Entire Gaza population at risk of famine, says UN

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?